Core Insights - AVITA Medical, Inc. reaffirms that the RECELL® System significantly reduces hospital length of stay (LOS) by an average of 36% compared to traditional split thickness skin grafts (STSG) for adult patients with deep partial thickness burns [1][2][8] - The RECELL System is clinically validated as a cost-effective option in modern burn management, improving patient outcomes and hospital efficiency [2][5] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions, with the RECELL System at the forefront [6] - The RECELL System utilizes a patient's own skin to create an autologous skin cell suspension autograft, enhancing recovery at the point of care [2][6] Economic Impact - The use of RECELL is associated with potential per patient cost savings exceeding $42,000, based on an average daily inpatient bed cost of $7,554 [3] - The reduction in LOS allows hospitals to treat 13 more patients per bed annually compared to STSG treatment [3] Clinical Findings - A matched analysis of 741 adults showed that RECELL-treated patients had an average 5.6-day reduction in hospital LOS, representing a 36% decrease compared to STSG [2][8] - In 2023, U.S. burn cases consumed over 110,000 ICU days, costing more than $676 million, highlighting the need for efficient burn care solutions [4] Regulatory Approvals - The RECELL System is approved for various applications in international markets, including thermal burn and trauma wounds, with approvals in Australia, Europe, and Japan [7]

Core Points - AVITA Medical, Inc. has successfully completed a private placement to raise approximately US$15 million (around A$23 million) through the issuance of about 17.2 million New CDIs at an offer price of A$1.32 per New CDI, which represents an 11% discount to the last closing price of A$1.48 on August 12, 2025 [1][4][8] - The proceeds from the placement will be utilized for working capital and to support the growth of the Company's therapeutic acute wound portfolio, expected to sustain operations until free cash flow begins in 2026 [2] - The New CDIs are set to be settled on August 19, 2025, and will commence trading on the ASX on August 20, 2025, ranking equally with existing CDIs [5][6] Company Overview - AVITA Medical is a leading company in therapeutic acute wound care, focusing on innovative solutions that enhance wound healing and accelerate patient recovery [7] - The company's flagship product, the RECELL® System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells [7][9] - AVITA Medical also holds exclusive rights to manufacture and distribute PermeaDerm® and Cohealyx™, further expanding its product offerings in the wound care market [9]

Financial Results - Commercial revenue for Q2 2025 was $18.4 million, representing a 21% increase compared to $15.2 million in Q2 2024 [8][12] - Net loss for Q2 2025 improved to $9.9 million, or a loss of $0.38 per share, compared to a net loss of $15.4 million, or a loss of $0.60 per share in Q2 2024 [8][16] - Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses [8][14] Business Update - Demand for RECELL was dampened in the first half of 2025 due to delays in provider payments, leading to a backlog of unpaid claims [6][9] - The Centers for Medicare and Medicaid Services (CMS) approved New Technology Add-on Payment (NTAP) for the RECELL System for inpatient trauma wounds [8][10] - AVITA anticipates recovery in RECELL demand in the second half of 2025 as claims backlog is resolved [10] Clinical Highlights - RECELL reduces hospital stays by 36% based on real-world analysis from the national burn registry over five years [5][8] - Cohealyx achieves autograft readiness in as little as five days, with first clinical results published [8] Strategic Developments - The company amended credit terms with OrbiMed, lowering revenue covenants and issuing common stock in lieu of cash payment [8][11] - Michael Tarnoff, MD, FACS, was appointed to the Board of Directors, bringing extensive healthcare leadership experience [8] Guidance Adjustments - Full-year 2025 revenue guidance was revised to a range of $76 million to $81 million, down from previous guidance of $100 million to $106 million [11][15] - The company expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026, later than previously anticipated [11][15]

Core Insights - AVITA Medical, Inc. will report its second quarter 2025 financial results on August 7, 2025, after U.S. market close [1] - A conference call and webcast will be held on the same day to discuss financial results and business highlights [1] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions [3] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin Cells [3] - In the U.S., AVITA Medical has exclusive rights to manufacture and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] International Market Presence - The RECELL System is approved for various applications in international markets, including burns and full-thickness skin defects [4] - The system is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan [4]

Core Insights - AVITA Medical, Inc. will host its inaugural Acute Wound Care Showcase 2025 on May 13, 2025, via webcast [1] - The event will feature presentations from key executives and provide an overview of the company's approach to acute wound care [2][3] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on optimizing wound healing and accelerating patient recovery [4] - The RECELL® System is a key product, approved by the FDA for treating thermal burn wounds and full-thickness skin defects, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - The company also markets Cohealyx™, a collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix, in the U.S. [4] Product Portfolio - The Acute Wound Care Showcase will highlight the company's product portfolio, including RECELL®, Cohealyx™, and PermeaDerm® [2] - The RECELL System is approved for various applications internationally, including burns and full-thickness skin defects, with regulatory approvals in Australia, Europe, and Japan [5] Event Details - The event will include testimonials from physicians and patients, showcasing the clinical and economic benefits of AVITA's technologies [3] - A live Q&A session will conclude the event, allowing for direct engagement with attendees [3]